The effect of short-term α-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics
References (24)
- et al.
Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor
Metabolism
(1981) - et al.
Reappraisal of the role of insulin in hypertriglyceridemia
Am J Med
(1974) - et al.
Receptor and postreceptor defects contribute to the insulin resistance in non-insulin resistance in non-insulin dependent diabetes mellitus
J Clin Invest
(1981) - et al.
Potentiation of insulin secretory responses by plasma glucose levels in man: Evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation
J Clin Endocrinol Metab
(1979) - et al.
Metabolic effects of very low caloric diet (VLCD) therapy in obese Type II diabetics (NIDDM)
Clin Res
(1984) - et al.
The acute and chronic effects of sulfonylurea therapy in Type II diabetics
Diabetes
(1984) - et al.
Insulin treatment reverses the insulin resistance of Type II diabetes mellitus
Diabetes Care
(1982) - et al.
Scope and specificity of Acarbose in slowing carbohydrate absorption in man
Diabetes
(1981) - et al.
Acarbose treatment of non-insulin dependent diabetes mellitus
Arch Intern Med
(1984) Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance
Diabetes
(1979)
Glucose clamp technique: A method for quantifying insulin secretion and resistance
Am J Physiol
Gluconeogenesis: Methodological approaches in vivo
Cited by (35)
GCMS fingerprints and phenolic extracts of Allium sativum inhibit key enzymes associated with type 2 diabetes
2023, Journal of Taibah University Medical SciencesCitation Excerpt :The digestion of carbohydrates is a complex phenomenon involving various metabolic enzymes. In the enzyme machinery responsible for this event, α-glucosidase and α-amylase are commonly used for breaking down oligosaccharides into their monomeric glucose units, which are the absorbable form taken up by transporters on the intestinal epithelium and transferred into the blood.39 Because high blood glucose facilitates susceptability to type 2 diabetes and its subsequent complications, preventing elevations in blood glucose is critical for diabetes therapy.
Loss of Sucrase-Isomaltase Function Increases Acetate Levels and Improves Metabolic Health in Greenlandic Cohorts
2022, GastroenterologyCitation Excerpt :In this other cohort, we also found that homozygous carriers had markedly higher levels of circulating acetate, which was likely only detectable due to the lack of fasting in these participants. Notably, the effect of the naturally occurring specific loss of SI function seemed to be greater on weight and levels of triglycerides compared with drug-induced unspecific inhibition of α-glucosidases by acarbose, voglibose, or miglitol,32–38 and the impact of loss of SI function on triglyceride levels was equal to the reported effect of the lipid-lowering drug statins.39,40 Moreover, altered high-density lipoprotein metabolism among homozygous carriers suggested increased health-promoting removal of cholesterol from extrahepatic tissues.
Acarbose attenuates postprandial hyperlipidemia: investigation in an intestinal absorptive cell model
2009, Metabolism: Clinical and ExperimentalOral administration of rac-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial
1999, Free Radical Biology and MedicineEffect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus
1998, Diabetes Research and Clinical PracticeImprovement of insulin sensitivity and dyslipidemia with a new α- glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects
1996, Metabolism: Clinical and Experimental